IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2024
- 30 July 2024 - 1 mins read
Aggregated presentation by day and by market
| Purchases of own shares from July 22th to 26th, 2024 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 22/07/2024 | FR0010259150 | 4 826 | 110,5421 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 22/07/2024 | FR0010259150 | 2 174 | 110,5586 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 23/07/2024 | FR0010259150 | 4 266 | 110,5508 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 23/07/2024 | FR0010259150 | 2 362 | 110,5066 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 23/07/2024 | FR0010259150 | 492 | 110,4112 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 23/07/2024 | FR0010259150 | 328 | 110,4091 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2024 | FR0010259150 | 4 000 | 110,3341 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2024 | FR0010259150 | 2 000 | 110,5260 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 25/07/2024 | FR0010259150 | 17 547 | 103,9803 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 25/07/2024 | FR0010259150 | 5 156 | 103,5941 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 25/07/2024 | FR0010259150 | 1 054 | 103,6816 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 25/07/2024 | FR0010259150 | 911 | 103,3653 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 26/07/2024 | FR0010259150 | 14 995 | 102,8893 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 26/07/2024 | FR0010259150 | 6 886 | 103,2035 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 26/07/2024 | FR0010259150 | 1 112 | 103,2192 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 26/07/2024 | FR0010259150 | 1 795 | 103,4211 | AQEU |
| TOTAL | 69 904 | 105,5076 | ||||
Attachment
07 November 2024
1 mins read
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 October 2024
1 mins read
Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
18 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
04 September 2024
1 mins read
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
30 August 2024
1 mins read
Testing video 1
30 August 2024
1 mins read
Testing video 3
30 August 2024
1 mins read
Testing video 2
13 August 2024
1 mins read